Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387032788> ?p ?o ?g. }
- W4387032788 abstract "Biliary tract cancers are rare aggressive malignancies typically diagnosed when the disease is metastatic or unresectable, precluding curative treatment.We aimed to identify treatment guidelines, real-world treatment patterns, and outcomes for unresectable advanced or metastatic biliary tract cancers in adult patients.Databases (MEDLINE, Embase, Cochrane Database of Systematic Reviews) were systematically searched between 1 January, 2000 and 25 November, 2021, and supplemented by hand searches. Eligible records were (1) treatment guidelines and (2) observational studies reporting real-world treatment outcomes, for unresectable advanced or metastatic biliary tract cancers. Only studies performed in the UK, Germany, France, Australia, Canada and South Korea were extracted, to moderate the number of records for synthesis while maintaining representation of a wide range of biliary tract cancer incidences.A total of 66 relevant unique full-text records were extracted, including 16 treatment guidelines and 50 observational studies. Among guidelines, chemotherapies were most strongly recommended at first line (1L); the combination of gemcitabine and cisplatin (GEMCIS) was recommended as the standard of care in 1L. Recommendations for systemic chemotherapy in the second line (2L) conflicted because of uncertainties around survival benefit. Guidelines on further lines of treatment included a range of locoregional modalities and stenting or best supportive care without providing clear recommendations because of data paucity. Fifty observational studies reporting real-world treatment outcomes were extracted, of which 25 (50%) and 9 (18%) reported outcomes in 1L and 2L, respectively; 22 (44%) reported outcomes for treatments described as 'palliative'. In 1L, outcomes for systemic chemotherapy were most frequently described (23/25 studies), and GEMCIS was the most common systemic chemotherapy used (10/23 studies) in line with guidelines. Median overall survival with 1L systemic chemotherapy was < 12 months in most studies (16/23; range 4.7-22.3 months). Most 2L studies (10/11) described outcomes for systemic chemotherapy, most commonly for fluoropyrimidine-based regimen (5/10 studies). Median overall survival with 2L systemic chemotherapy was < 12 months in 5/10 studies (range 4.9-21.5 months). Median progression-free survival was reported more rarely than median overall survival. Some studies with small sample sizes or specifically selected patient populations (e.g. higher performance status, or patients who had already responded to treatment) achieved higher median overall survival.At the time of this review, treatment options for unresectable advanced or metastatic biliary tract cancers confer poor real-world survival. For over a decade, GEMCIS remained the 1L standard of care, highlighting the lack of therapeutic innovation in this indication and the urgent unmet need for novel treatments with improved outcomes in this aggressive condition. Additional observational studies are needed to further understand the effectiveness of currently available treatments, as well as newly available therapies including the addition of immunotherapy in the evolving treatment landscape." @default.
- W4387032788 created "2023-09-27" @default.
- W4387032788 creator A5000721261 @default.
- W4387032788 creator A5000772319 @default.
- W4387032788 creator A5007148541 @default.
- W4387032788 creator A5017558307 @default.
- W4387032788 creator A5073485212 @default.
- W4387032788 creator A5077517862 @default.
- W4387032788 creator A5089884515 @default.
- W4387032788 date "2023-09-26" @default.
- W4387032788 modified "2023-09-27" @default.
- W4387032788 title "A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer" @default.
- W4387032788 cites W138318583 @default.
- W4387032788 cites W1482473513 @default.
- W4387032788 cites W1589114640 @default.
- W4387032788 cites W180040669 @default.
- W4387032788 cites W1849393714 @default.
- W4387032788 cites W1890090785 @default.
- W4387032788 cites W1970368087 @default.
- W4387032788 cites W1976926907 @default.
- W4387032788 cites W1979089897 @default.
- W4387032788 cites W1982336985 @default.
- W4387032788 cites W1985577239 @default.
- W4387032788 cites W1990634202 @default.
- W4387032788 cites W2000422683 @default.
- W4387032788 cites W2011387799 @default.
- W4387032788 cites W2019130341 @default.
- W4387032788 cites W2025958291 @default.
- W4387032788 cites W2026768024 @default.
- W4387032788 cites W2028903238 @default.
- W4387032788 cites W2036831774 @default.
- W4387032788 cites W2039461238 @default.
- W4387032788 cites W2042373080 @default.
- W4387032788 cites W2043242989 @default.
- W4387032788 cites W2068140421 @default.
- W4387032788 cites W2079283960 @default.
- W4387032788 cites W2087336559 @default.
- W4387032788 cites W2087669041 @default.
- W4387032788 cites W2090159789 @default.
- W4387032788 cites W2106550415 @default.
- W4387032788 cites W2115261608 @default.
- W4387032788 cites W2116856076 @default.
- W4387032788 cites W2123744108 @default.
- W4387032788 cites W2124873797 @default.
- W4387032788 cites W2129688566 @default.
- W4387032788 cites W2141078344 @default.
- W4387032788 cites W2154294796 @default.
- W4387032788 cites W2200769448 @default.
- W4387032788 cites W2283978743 @default.
- W4387032788 cites W2319550695 @default.
- W4387032788 cites W2325613386 @default.
- W4387032788 cites W2344147562 @default.
- W4387032788 cites W2344610008 @default.
- W4387032788 cites W2414177364 @default.
- W4387032788 cites W2416923768 @default.
- W4387032788 cites W2526881395 @default.
- W4387032788 cites W2544695096 @default.
- W4387032788 cites W2553739594 @default.
- W4387032788 cites W2576296809 @default.
- W4387032788 cites W2609866200 @default.
- W4387032788 cites W2622965133 @default.
- W4387032788 cites W2624727904 @default.
- W4387032788 cites W2745443608 @default.
- W4387032788 cites W2752583521 @default.
- W4387032788 cites W2770576134 @default.
- W4387032788 cites W2794383079 @default.
- W4387032788 cites W2887019214 @default.
- W4387032788 cites W2895049718 @default.
- W4387032788 cites W2895314670 @default.
- W4387032788 cites W2908115090 @default.
- W4387032788 cites W2909422671 @default.
- W4387032788 cites W2913356568 @default.
- W4387032788 cites W2913986521 @default.
- W4387032788 cites W2922428045 @default.
- W4387032788 cites W2944828176 @default.
- W4387032788 cites W2945809308 @default.
- W4387032788 cites W2953729061 @default.
- W4387032788 cites W2954759555 @default.
- W4387032788 cites W2998808298 @default.
- W4387032788 cites W3004366889 @default.
- W4387032788 cites W3004452429 @default.
- W4387032788 cites W3009889682 @default.
- W4387032788 cites W3013639183 @default.
- W4387032788 cites W3032507003 @default.
- W4387032788 cites W3033337702 @default.
- W4387032788 cites W3033656623 @default.
- W4387032788 cites W3037606541 @default.
- W4387032788 cites W3037735720 @default.
- W4387032788 cites W3046934284 @default.
- W4387032788 cites W3088596511 @default.
- W4387032788 cites W3118964091 @default.
- W4387032788 cites W3120400593 @default.
- W4387032788 cites W3141256924 @default.
- W4387032788 cites W3165128187 @default.
- W4387032788 cites W3190081651 @default.
- W4387032788 cites W3203839840 @default.
- W4387032788 cites W3205942556 @default.
- W4387032788 cites W4220981238 @default.
- W4387032788 cites W4223894679 @default.
- W4387032788 cites W4225549365 @default.